Loading…
Acurx Pharmaceuticals, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ACXP.
▼ -98.6% over 5Y.
today you would have $13.23▼ -98.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $2.49 | $16.28 | $76.60 | $79.60 | |
| P/B | 9.1x | 1.1x | 22.5x | 11.9x | 6.3x |
| EPS | -$5.32 | -$17.45 | -$23.00 | -$22.40 | |
| ROE | -238.85% | -151.21% | -2292.74% | -312.38% | -165.31% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENVBEnveric Biosciences, Inc. | $1.37 | — | 0.3x | — | -170.04% | $6.13M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 | — | 0.8x | — | -42.52% | $6.27M |
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| XTLBXtl Biopharmaceuticals Ltd | $2.47 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| -29.30% |
| $6.07M |
| GELSGelteq Ltd | $0.56 | — | 0.6x | — | -42.93% | $5.95M |
| VNRXVolitionrx Ltd | $0.45 | — | — | — | — | $6.48M |